{"entity":{"id":"nct05867420","kind":"trial","name":"A Study of ASKG915 in Patients With Selected Advanced Solid Tumors.","aka":[],"tldr":"A phase 1/2 trial of Bevacizumab, Fruquintinib and Docetaxel in advanced solid tumours, run by AskGene Pharma, Inc., now recruiting.","summary":"A Study of ASKG915 in Patients With Selected Advanced Solid Tumors. is a phase 1/2 interventional study registered as NCT05867420 by AskGene Pharma, Inc., with 594 participants planned, started 2023-08-02 and due to reach its primary completion in 2026-12-31. Interventions recorded: ASKG915, Paclitaxel + Bevacizumab, Fruquintinib and Docetaxel.","status":"recruiting","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT05867420","url":"https://clinicaltrials.gov/study/NCT05867420"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["metastatic-cancer"],"sections":[],"technologies":[],"targets":[],"drugs":["bevacizumab","fruquintinib","docetaxel"],"companies":["askgene-pharma"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"notes":[],"nct":"NCT05867420","phase":"1/2","setting":"A Phase 1 Dose Escalation Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of ASKG915 in Patients With Selected Advanced Solid Tumors","sponsor":"AskGene Pharma, Inc.","enrolled":594,"outcomes":[]},"route":"/trials/nct05867420/","neighbours":{"cancer":[{"id":"metastatic-cancer","kind":"cancer","name":"Metastatic cancer (cancer that has spread)","route":"/cancers/metastatic-cancer/"}],"drug":[{"id":"bevacizumab","kind":"drug","name":"Bevacizumab","route":"/drugs/bevacizumab/"},{"id":"docetaxel","kind":"drug","name":"Docetaxel","route":"/drugs/docetaxel/"},{"id":"fruquintinib","kind":"drug","name":"Fruquintinib","route":"/drugs/fruquintinib/"}],"company":[{"id":"askgene-pharma","kind":"company","name":"AskGene Pharma","route":"/companies/askgene-pharma/"}]}}